市場調査レポート

商品コード

1447725

カンナビジオール市場の評価：生物種・投与経路・形態・治療用途・エンドユーザー・地域別の機会および予測 (2017～2031年)

Cannabidiol Market Assessment, By Species, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月11日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 227 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のカンナビジオールの市場規模は、2023年の80億4,000万米ドルから、2024年から2031年の予測期間中は18%のCAGRで推移し、2031年には302億2,000万米ドルの規模に成長すると予測されています。

世界のカンナビジオール市場の発展は、ヘルスケア産業におけるCBDの医薬品用途の拡大や、さまざまな医療状態におけるCBDの潜在的利点を研究するための大手企業によるR&Dの増加など、さまざまな要因によって推進されています。てんかんのような健康状態に対するCBDの安全な使用に関して、人々の間で受け入れられていることも、同市場の世界の成長につながっています。さまざまなな国でCBDの合法化が進み、カンナビジオール市場への投資に対する公的機関や民間機関の関心が高まっています。主要企業、新興企業、共同事業ベンチャーの存在とこれらの企業によるM&A、提携、販売契約、頻繁な新製品の発売などが世界のカンナビジオール市場の成長を推進しています。

世界のカンナビジオール市場は、不安、うつ病、慢性疼痛、てんかんなどの薬としてのCBDの応用拡大から、大きな成長を遂げています。CBDは、治療上の利点をもたらす大きな可能性があるため、CBDオイル、カプセル、外用クリームとして製薬業界で広く使用されています。その結果、いくつかの公的機関や民間団体がCBDの治療上の利点をさらに見出すためにR&D活動への投資を増やしています。ここ数年、患者や医療提供者の間で薬用目的でのCBDの使用が受け入れられつつあり、CBD市場の需要拡大に繋がっています。

有利な規制の枠組みも世界のCBD市場を強化する上で重要な役割を果たしています。さまざまなな国において、薬用目的でのCBDの使用が合法化されつつあります。さらに、M&Aや企業間の提携契約、主要企業による一貫した革新的な製品の発売、新規参入企業などによる頻繁なコラボレーション活動も、世界のカンナビジオール市場をさらに促進しています。

メンタルヘルスの問題の増加

世界人口の間で不安やうつ病などの精神疾患の数が増加しており、カンナビジオールの需要が急増しています。世界保健機関 (WHO) は、うつ病などの精神疾患は今日の生活においてよくある健康状態になっていると述べています。世界全体では、人口の約3.8％がうつ病に罹患しており、成人の5％、60歳以上の5.7％がうつ病に罹患しています。

有利な規制枠組み

CBDベースの製品に対する需要の高まりに伴い、FDAなどの規制機関では、医療におけるCBD製品の倫理的で安全な使用をサポートするための新たな規制の道筋を改善し、もたらすことが検討されてきました。2023年1月、米国FDAは、カンナビジオールを含む商品に関する規制の枠組みを再評価すると発表しています。

当レポートでは、世界のカンナビジオールの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
生物種
- インディカ
- サティバ
- ハイブリッド
投与経路別
- 経口
- 局所
- その他
形態別
- オイル
- カプセル
- チンキ剤
治療用途別
- 癌
- 片頭痛
- てんかん
- 不安・うつ病
- その他
エンドユーザー別
- 製薬会社
- 病院薬局
- オンライン薬局
- 小売店
- R&Dセンター
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
企業別の市場シェア

第5章世界のカンナビジオール市場の展望：地域別

北米
欧州
南米
アジア太平洋
中東・アフリカ

第6章市場マッピング

製品タイプ別
手法別
用途別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長阻害要因 (課題・抑制要因)

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析（主要企業）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Charlotte's Web, Inc.
Medical Marijuana, Inc.
Jazz Pharmaceuticals plc.
Aurora Cannabis Inc.
Hemp Synergistics LLC
Canopy Growth Corporation
Isodiol International Inc.
Gaia Botanicals, LLC, d/b/a Bluebird Botanicals
CV Sciences, Inc.
High Tide Inc.

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 2.Global Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 3.Global Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 4.Global Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 5.Global Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 6.Global Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 7.Global Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 8.Global Cannabidiol Market Share (%), By Region, 2017-2031F
Figure 9.North America Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 10.North America Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 11.North America Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 12.North America Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 13.North America Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 14.North America Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 15.North America Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 16.North America Cannabidiol Market Share (%), By Country, 2017-2031F
Figure 17.United States Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 18.United States Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 19.United States Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 20.United States Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 21.United States Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 22.United States Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 23.United States Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 24.Canada Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 25.Canada Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 26.Canada Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 27.Canada Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 28.Canada Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 29.Canada Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 30.Canada Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 31.Mexico Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 32.Mexico Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 33.Mexico Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 34.Mexico Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 35.Mexico Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 36.Mexico Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 37.Mexico Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 38.Europe Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 39.Europe Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 40.Europe Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 41.Europe Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 42.Europe Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 43.Europe Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 44.Europe Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 45.Europe Cannabidiol Market Share (%), By Country, 2017-2031F
Figure 46.Germany Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 47.Germany Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 48.Germany Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 49.Germany Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 50.Germany Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 51.Germany Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 52.Germany Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 53.France Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 54.France Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 55.France Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 56.France Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 57.France Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 58.France Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 59.France Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 60.Italy Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 61.Italy Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 62.Italy Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 63.Italy Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 64.Italy Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 65.Italy Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 66.Italy Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 67.United Kingdom Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 68.United Kingdom Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 69.United Kingdom Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 70.United Kingdom Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 71.United Kingdom Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 72.United Kingdom Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 73.United Kingdom Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 74.Russia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 75.Russia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 76.Russia Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 77.Russia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 78.Russia Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 79.Russia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 80.Russia Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 81.Netherlands Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 82.Netherlands Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 83.Netherlands Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 84.Netherlands Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 85.Netherlands Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 86.Netherlands Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 87.Netherlands Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 88.Spain Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 89.Spain Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 90.Spain Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 91.Spain Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 92.Spain Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 93.Spain Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 94.Spain Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 95.Turkey Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 96.Turkey Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 97.Turkey Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 98.Turkey Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 99.Turkey Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 100.Turkey Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 101.Turkey Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 102.Poland Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 103.Poland Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 104.Poland Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 105.Poland Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 106.Poland Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 107.Poland Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 108.Poland Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 109.South America Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 110.South America Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 111.South America Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 112.South America Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 113.South America Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 114.South America Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 115.South America Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 116.South America Cannabidiol Market Share (%), By Country, 2017-2031F
Figure 117.Brazil Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 118.Brazil Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 119.Brazil Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 120.Brazil Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 121.Brazil Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 122.Brazil Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 123.Brazil Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 124.Argentina Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 125.Argentina Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 126.Argentina Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 127.Argentina Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 128.Argentina Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 129.Argentina Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 130.Argentina Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 131.Asia-Pacific Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 132.Asia-Pacific Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 133.Asia-Pacific Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 134.Asia-Pacific Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 135.Asia-Pacific Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 136.Asia-Pacific Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 137.Asia- Pacific Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 138.Asia-Pacific Cannabidiol Market Share (%), By Country, 2017-2031F
Figure 139.India Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 140.India Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 141.India Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 142.India Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 143.India Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 144.India Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 145.India Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 146.China Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 147.China Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 148.China Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 149.China Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 150.China Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 151.China Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 152.China Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 153.Japan Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 154.Japan Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 155.Japan Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 156.Japan Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 157.Japan Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 158.Japan Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 159.Japan Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 160.Australia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 161.Australia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 162.Australia Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 163.Australia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 164.Australia Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 165.Australia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 166.Australia Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 167.Vietnam Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 168.Vietnam Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 169.Vietnam Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 170.Vietnam Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 171.Vietnam Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 172.Vietnam Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 173.Vietnam Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 174.South Korea Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 175.South Korea Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 176.South Korea Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 177.South Korea Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 178.South Korea Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 179.South Korea Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 180.South Korea Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 181.Indonesia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 182.Indonesia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 183.Indonesia Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 184.Indonesia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 185.Indonesia Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 186.Indonesia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 187.Indonesia Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 188.Philippines Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 189.Philippines Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 190.Philippines Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 191.Philippines Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 192.Philippines Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 193.Philippines Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 194.Philippines Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 195.Middle East & Africa Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 196.Middle East & Africa Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 197.Middle East & Africa Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 198.Middle East & Africa Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 199.Middle East & Africa Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 200.Middle East & Africa Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 201.Middle East & Africa Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 202.Middle East & Africa Cannabidiol Market Share (%), By Country, 2017-2031F
Figure 203.Saudi Arabia Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 204.Saudi Arabia Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 205.Saudi Arabia Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 206.Saudi Arabia Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 207.Saudi Arabia Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 208.Saudi Arabia Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 209.Saudi Arabia Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 210.UAE Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 211.UAE Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 212.UAE Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 213.UAE Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 214.UAE Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 215.UAE Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 216.UAE Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 217.South Africa Cannabidiol Market, By Value, In USD Billion, 2017-2031F
Figure 218.South Africa Cannabidiol Market, By Volume, In Million Units, 2017-2031F
Figure 219.South Africa Cannabidiol Market Share (%), By Species, 2017-2031F
Figure 220.South Africa Cannabidiol Market Share (%), By Route of Administration, 2017-2031F
Figure 221.South Africa Cannabidiol Market Share (%), By Form, 2017-2031F
Figure 222.South Africa Cannabidiol Market Share (%), By Therapeutical Application, 2017-2031F
Figure 223.South Africa Cannabidiol Market Share (%), By End-user, 2017-2031F
Figure 224.By Species Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226.By Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227.By Therapeutical Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11132

Global cannabidiol market is projected to witness a CAGR of 18% during the forecast period 2024-2031, growing from USD 8.04 billion in 2023 to USD 30.22 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in the global cannabidiol market is being driven by various factors such as increased medicinal application of CBD in the healthcare industry and increased research and development by leading players to study the potential benefits of CBD in different medical conditions. Growing acceptance among people regarding the safe usage of CBD for health conditions such as epilepsy is leading to the growth of this market globally. Increased legalization of CBD across different countries is enhancing the interest of public and private organizations in investing in the cannabidiol market. The presence of several top players, new companies, and collaborative ventures such as mergers and acquisitions, partnerships, distribution agreements, and frequent new product launches are driving the growth of the global cannabidiol market.

The global cannabidiol market is undergoing significant growth due to the increasing application of CBD for medicinal purposes such as anxiety, depression, chronic pain, and epilepsy. CBD is widely used by the pharmaceutical industry as CBD oils, capsules, and topical creams, due to its huge potential in providing therapeutical advantages. As a result, several public and private organizations are increasingly investing in research and development activities to find out more therapeutical benefits of CBD. Over the years, there has been an increased acceptance of CBD usage for medicinal purposes among patients and healthcare providers, leading to a growing demand for the CBD market.

A favorable regulatory framework plays a crucial role in enhancing the global CBD market. There has been increased legalization of the usage of CBD for medicinal purposes across different countries. The act is enhancing and expanding the CBD market at a global level. Moreover, frequent collaboration activities such as mergers and acquisitions, partnership agreements between the companies, consistent innovative product launches by the key market players, along with new entrances, further propels the global cannabidiol market. In December 2023, Rare Cannabinoid Company announced the launch of THC + THCV Uplift Gummies. This product has been launched for the United States consumers to increase focus, energy, and control hunger.

Increasing Prevalence of Mental Health Problems

There has been a surge in demand for cannabidiol due to the rising number of mental illnesses such as anxiety and depression among the global population. Mental health conditions are not uncommon these days and affect a larger section of people from all over the world. The World Health Organization states that mental disorders such as depression have become a common health condition in today's life. Globally, around 3.8% of the population is affected by depression, includes 5% of adults and 5.7% of people aged 60 years and above.

WHO states that, globally, there are around 280 million people who suffer from depression. Depression is more common among women compared to men. Globally, 10% of pregnant and post-partum women experience depression every year. WHO states that every year more than 700,000 people die due to suicide. Several studies have shown the potential of CBD in managing depression and anxiety, which has substantially led to improvement in the health condition of the people. Hence, many organizations are incorporating CBD for developing CBD-based products.

Favorable Regulatory Framework

With the growing demand for CBD-based products, there has been consideration within the regulatory bodies such as FDA, to improve and bring new regulatory pathways to support the ethical and safe use of CBD-based products in the healthcare industry. In January 2023, the Food and Drug Administration in the United States announced that it is now re-evaluating the regulatory framework for goods containing cannabidiol. The FDA has determined that the current regulatory frameworks for foods and supplements do not apply to CBD and that a new regulatory approach is required to initiate a compromise between the requirement for consumer safety and people's desire to have access to CBD products. To create a new cross-agency approach to the regulation of these items, the FDA is ready to collaborate with Congress. This favorable change in the current regulatory systems is expected to accelerate the development of cannabidiol.

Consumption of CBD Oil is Witnessing Significant Demand

Among the form segments, CBD oil segment holds a significant market share in the global cannabidiol market. In comparison with other forms of cannabidiol, CBD oil has vast application areas such as in pain management, epilepsy, nutraceuticals and beauty. CBD oils are legal and easy to access, which makes it highly popular among manufacturers and consumers. Additionally, several leading players are launching CBD oils for various medical purposes in their product portfolio, which is enhancing the growth of the global cannabidiol market. For instance, in September 2023, Aurora Cannabis Inc., a Canada based medical cannabis company announced an expansion of its hemp-derived CBD portfolio in Brazil. The company is all set to launch full-spectrum, single-source 3% CBD oil, to cater to the need of the consumers in Brazil.

Application of CBD in Treating Epilepsy

Among the therapeutic application segment, CBD is widely used for the treatment of epilepsy and thus, the segment holds a significant market share in the overall global cannabidiol market. Cannabidiol has shown promising positive effects in the treatment of epilepsy, especially in certain epileptic syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. Regulatory bodies such as the European Medicines Agency and the U.S. Food and Drug Administration have approved CBD for use in certain epilepsy treatments.

Moreover, key market players are bringing new product launches in this segment to improve the health conditions of the patients, which is further accelerating the growth of the segment. In January 2023, Medical Marijuana, Inc. subsidiary "HempMeds Brasil" successfully launched two new CBD-based products in Brazil to help in the treatment process of epilepsy. HempMeds Brasil is authorized to provide its CBD-based products, under medical prescription to aid in the management of diseases such as epilepsy, Parkinson's, chronic pain, and multiple sclerosis.

North America Dominates Global Cannabidiol Market

North America holds the largest share in global cannabidiol market, due to various factors such as the presence of major manufacturers including Medical Marijuana Inc. and Tilray Inc., increased acceptance among healthcare providers and people regarding using CBD-based products for medical conditions such as anxiety, depression, epilepsy, and pain management driving high demand for cannabidiol. Additionally, favorable laws regarding the usage of CBD products in most of the countries in North America are enhancing the growth of the market.

Medical Marijuana Inc., stated that in the United States, there are around 33 states, that have legalized safe usage of marijuana and there are more states that are expected to receive permission to legalize cannabinoid usage in the future. Consequently, along with the re-formation of federal law, it is expected that North America will further undergo tremendous growth in the cannabidiol market and will maintain its leadership in the forecast period as well.

Future Market Scenario (2024 - 2031F)

The global cannabidiol market is expected to grow in the future due to multiple factors. The increasing prevalence of anxiety and depression among the population has enhanced the company's focus in developing CBD-based products that can help with relieving mental stress among the users. Increased acceptance among healthcare providers regarding the capabilities of CBD in the treatment of anxiety, depression, and epilepsy has enabled pharmaceutical companies to increase investments in the market. There has been a surge in research and development activities in the market to further explore the potential benefits of CBD in patient treatments. Collaborative ventures among the companies, improved and supportive regulatory framework, and new entrants have spurred growth in the global cannabidiol market. According to an article published in the "Hartford Business Journal" many CBD companies are planning to start their operations in 2023 and 2024. Along with it, new retailers, manufacturers, and products are expected to enter the cannabidiol market, which will further assist in driving the market growth.

Key Players Landscape and Outlook

In cannabidiol market, several pharmaceutical companies are consistently establishing strategic partnerships, and distribution agreements, which play a pivotal role in driving the demand for cannabidiol products. These partnerships enable firms to gain informative insights regarding the market, take advantage of each other's resources, markets, and technologies, and invest in research and development activities to bring advancements in the market. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expertise product development and contribute to the enduring and robust growth of the global market.

For instance, in August 2023, Medical Marijuana, Inc., announced that Kannaway, which is its subsidiary, completed acquisition of a Japan based network marketing company "EXfuse, LLC, dba KZ1". The acquisition will expand the company's business in Japan and the KZ1's premium products such as nootropics-based products enhancing the company's CBD product portfolio. The partnership further aims to bring innovative product launches in their various business segments such as natural health, beauty, and CBD products.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Cannabidiol Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1.By Value
- 4.1.2.By Volume
4.2.By Species
- 4.2.1.Indica
- 4.2.2.Sativa
- 4.2.3.Hybrid
4.3.By Route of Administration
- 4.3.1.Oral
- 4.3.2.Topical
- 4.3.3.Others
4.4.By Form
- 4.4.1.Oils
- 4.4.2.Capsules
- 4.4.3.Tinctures
4.5.By Therapeutic Application
- 4.5.1.Cancer
- 4.5.2.Migraine
- 4.5.3.Epilepsy
- 4.5.4.Anxiety and Depression
- 4.5.5.Others
4.6.By End-user
- 4.6.1.Pharmaceutical Companies
- 4.6.2.Hospital Pharmacies
- 4.6.3.Online Pharmacies
- 4.6.4.Retail Stores
- 4.6.5.Research and Development Centers
- 4.6.6.Others
4.7.By Region
- 4.7.1.North America
- 4.7.2.Europe
- 4.7.3.Asia-Pacific
- 4.7.4.South America
- 4.7.5.Middle East and Africa
4.8.By Company Market Share (%), 2023

5.Global Cannabidiol Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Species
  - 5.1.2.1.Indica
  - 5.1.2.2.Sativa
  - 5.1.2.3.Hybrid
- 5.1.3.By Route of Administration
  - 5.1.3.1.Oral
  - 5.1.3.2.Topical
  - 5.1.3.3.Others
- 5.1.4.By Form
  - 5.1.4.1.Oils
  - 5.1.4.2.Capsules
  - 5.1.4.3.Tinctures
- 5.1.5.By Therapeutic Application
  - 5.1.5.1.Cancer
  - 5.1.5.2.Migraine
  - 5.1.5.3.Epilepsy
  - 5.1.5.4.Anxiety and Depression
  - 5.1.5.5.Others
- 5.1.6.By End-user
  - 5.1.6.1.Pharmaceutical Companies
  - 5.1.6.2.Hospital Pharmacies
  - 5.1.6.3.Online Pharmacies
  - 5.1.6.4.Retail Stores
  - 5.1.6.5.Research and Development Centers
  - 5.1.6.6.Others
- 5.1.7.United States*
  - 5.1.7.1.Market Size & Forecast
  - 5.1.7.1.1.By Value
  - 5.1.7.1.2.By Volume
  - 5.1.7.2.By Species
  - 5.1.7.2.1.Indica
  - 5.1.7.2.2.Sativa
  - 5.1.7.2.3.Hybrid
  - 5.1.7.3.By Route of Administration
  - 5.1.7.3.1.Oral
  - 5.1.7.3.2.Topical
  - 5.1.7.3.3.Others
  - 5.1.7.4.By Form
  - 5.1.7.4.1.Oils
  - 5.1.7.4.2.Capsules
  - 5.1.7.4.3.Tinctures
  - 5.1.7.5.By Therapeutic Application
  - 5.1.7.5.1.Cancer
  - 5.1.7.5.2.Migraine
  - 5.1.7.5.3.Epilepsy
  - 5.1.7.5.4.Anxiety and Depression
  - 5.1.7.5.5.Others
  - 5.1.7.6.By End-user
  - 5.1.7.6.1.Pharmaceutical Companies
  - 5.1.7.6.2.Hospital Pharmacies
  - 5.1.7.6.3.Online Pharmacies
  - 5.1.7.6.4.Retail Pharmacies
  - 5.1.7.6.5.Research and Development Centers
  - 5.1.7.6.6.Others
- 5.1.8.Canada
- 5.1.9.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Netherlands
- 5.2.6.Spain
- 5.2.7.Turkey
- 5.2.8.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Australia
- 5.3.4.Vietnam
- 5.3.5.South Korea
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.South Africa

6.Market Mapping, 2023

6.1.By Species
6.2.By Route of Administration
6.3.By Form
6.4.By Therapeutic Application
6.5.By End-user
6.6.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Clinical Trials
9.2.Patent Landscape
9.3.Regulatory Approvals
9.4.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Charlotte's Web, Inc.
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.Medical Marijuana, Inc.
13.3.Jazz Pharmaceuticals plc.
13.4.Aurora Cannabis Inc.
13.5.Hemp Synergistics LLC
13.6.Canopy Growth Corporation
13.7.Isodiol International Inc.
13.8.Gaia Botanicals, LLC, d/b/a Bluebird Botanicals
13.9.CV Sciences, Inc.
13.10.High Tide Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

カンナビジオール市場の評価：生物種・投与経路・形態・治療用途・エンドユーザー・地域別の機会および予測 (2017～2031年)

Cannabidiol Market Assessment, By Species, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のカンナビジオール市場の展望

第5章世界のカンナビジオール市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Cannabidiol Market Outlook, 2017-2031F

5.Global Cannabidiol Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

カンナビジオール市場の評価：生物種・投与経路・形態・治療用途・エンドユーザー・地域別の機会および予測 (2017～2031年)

Cannabidiol Market Assessment, By Species, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のカンナビジオール市場の展望

第5章 世界のカンナビジオール市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Cannabidiol Market Outlook, 2017-2031F

5.Global Cannabidiol Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のカンナビジオール市場の展望

第5章世界のカンナビジオール市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項